ATP and cancer immunosurveillance

Abstract

While intracellular adenosine triphosphate (ATP) occupies a key position in the bioenergetic metabolism of all the cellular compartments that form the tumor microenvironment (TME), extracellular ATP operates as a potent signal transducer. The net effects of purinergic signaling on the biology of the TME depend not only on the specific receptors and cell types involved, but also on the activation status of cis‐ and trans‐regulatory circuitries. As an additional layer of complexity, extracellular ATP is rapidly catabolized by ectonucleotidases, culminating in the accumulation of metabolites that mediate distinct biological effects. Here, we discuss the molecular and cellular mechanisms through which ATP and its degradation products influence cancer immunosurveillance, with a focus on therapeutically targetable circuitries.

Cancer evolution: Darwin and beyond

“…The observation that certain cancer types or cancer subtypes metastasise to specific locations, a fact that cannot be solely be explained by circulation patterns, further reinforces the idea that tumours require particular environments for their growth and survival, even in later stages of cancer evolution (Nguyen et al , 2009). These are only but a few examples of how the TME can affect cancer initiation and evolution, as this topic is amply discussed in other reviews of this series (see Kepp et al , 2021; Parker et al , 2021).…”

Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy

“…Therefore, more in-depth study of the regulatory processes of nucleotide metabolism has important theoretical and clinical significance. Moreover, recent studies have shown that abnormal nucleotide metabolism not only accelerates the development of tumors but also alters the normal immune response in the tumor microenvironment (TME), indicating the potential effectiveness of targeting nucleotide metabolism to enhance immunotherapy [ 5 – 7 ]. This review provides an overview of nucleotide metabolism and its role in cancer and emphasizes that nucleotide metabolism is a therapeutic target not only for chemotherapy but also for enhancing the efficacy of cancer immunotherapy.…”

Trial watch: intratumoral immunotherapy

“… 15 , 190 , 191 Since this first report on ICD, multiple cancer treatment modalities have been reported to be endowed with such propensity. 192 , 193 They include additional chemotherapeutics (e.g. cyclophosphamide and oxaliplatin), certain physical cues (e.g.…”